Current Knowledge on Canine Atopic Dermatitis

2021 ◽  
Vol 2 ◽  
pp. 101-115
Author(s):  
Catherine A. Outerbridge ◽  
Tyler J.M. Jordan
Keyword(s):  
Atopic Dermatitis ◽  
Current Knowledge ◽  
Canine Atopic Dermatitis

scholarly journals IgE reactivity to Pacific cod (Gadus macrocephalus) fish allergens in dogs with canine atopic dermatitis

2019 ◽  
Vol 143 (2) ◽  
pp. AB67
Author(s):  
Ichiro Imanishi ◽  
Jumpei Uchiyama ◽  
Takako Matsuda ◽  
Keijiro Mizukami ◽  
Hidekatsu Shimakura ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pacific Cod ◽  
Canine Atopic Dermatitis ◽  
Ige Reactivity ◽  
Pacific Cod Gadus Macrocephalus ◽  
Gadus Macrocephalus

scholarly journals Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis

Cells ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 1392
Author(s):  
Hidaya A. Kader ◽  
Muhammad Azeem ◽  
Suhib A. Jwayed ◽  
Aaesha Al-Shehhi ◽  
Attia Tabassum ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Skin Diseases ◽  
Current Knowledge ◽  
Treatment Strategies ◽  
Developed Countries ◽  
Food Allergies ◽  
Th2 Response ◽  
Therapeutic Outcomes ◽  
Environmental Agents ◽  
Novel Treatment Strategies

Atopic dermatitis (AD) is one of the most prevalent inflammatory disease among non-fatal skin diseases, affecting up to one fifth of the population in developed countries. AD is characterized by recurrent pruritic and localized eczema with seasonal fluctuations. AD initializes the phenomenon of atopic march, during which infant AD patients are predisposed to progressive secondary allergies such as allergic rhinitis, asthma, and food allergies. The pathophysiology of AD is complex; onset of the disease is caused by several factors, including strong genetic predisposition, disrupted epidermal barrier, and immune dysregulation. AD was initially characterized by defects in the innate immune system and a vigorous skewed adaptive Th2 response to environmental agents; there are compelling evidences that the disorder involves multiple immune pathways. Symptomatic palliative treatment is the only strategy to manage the disease and restore skin integrity. Researchers are trying to more precisely define the contribution of different AD genotypes and elucidate the role of various immune axes. In this review, we have summarized the current knowledge about the roles of innate and adaptive immune responsive cells in AD. In addition, current and novel treatment strategies for the management of AD are comprehensively described, including some ongoing clinical trials and promising therapeutic agents. This information will provide an asset towards identifying personalized targets for better therapeutic outcomes.

Evaluation of the cutaneous expression of IL-17, IL-22, IL-31, and their receptors in canine atopic dermatitis

2021 ◽  
Vol 136 ◽  
pp. 74-80
Author(s):  
Sayaka Shiomitsu ◽  
James Gillen ◽  
Salvatore Frasca ◽  
Domenico Santoro
Keyword(s):  
Atopic Dermatitis ◽  
Canine Atopic Dermatitis

Molecular pathogenesis and clinical implications of eczema herpeticum

2008 ◽  
Vol 10 ◽  
Author(s):  
Caroline Bussmann ◽  
Wen-Ming Peng ◽  
Thomas Bieber ◽  
Natalija Novak
Keyword(s):  
Atopic Dermatitis ◽  
Age Of Onset ◽  
Current Knowledge ◽  
Allergen Challenge ◽  
Skin Lesions ◽  
Molecular Pathogenesis ◽  
Type I Interferons ◽  
Total Serum ◽  
Type I ◽  
Eczema Herpeticum

A subgroup of patients with atopic dermatitis develops one or more episodes of a severe viral skin infection caused by herpes simplex virus superimposed on eczematous skin lesions. This condition is named atopic dermatitis complicated by eczema herpeticum. Characteristic features of patients developing eczema herpeticum include an early age of onset of atopic dermatitis with a persistent and severe course into adulthood, predilection for eczematous skin lesions in the head and neck area, elevated total serum IgE levels and increased allergen sensitisation. Deficiencies at the level of both the innate and the adaptive immune system, which have been identified in atopic dermatitis, are much more pronounced in this subgroup. Predisposing cellular factors include a reduced number of plasmacytoid dendritic cells in the epidermis and a modified capacity of these cells to produce type I interferons after allergen challenge. In addition, lower levels of antimicrobial peptides in the skin of atopic dermatitis patients, resulting in part from a Th2-prone micromilieu, contribute to the lack of an effective defence against viral attack. In this review, we summarise the current knowledge of the molecular pathogenesis of eczema herpeticum.

Expression of thymic stromal lymphopoietin in canine atopic dermatitis

2013 ◽  
Vol 24 (1) ◽  
pp. 54-e14 ◽  
Author(s):  
Jolanta Klukowska-Rötzler ◽  
Ludovic Chervet ◽  
Eliane J. Müller ◽  
Petra Roosje ◽  
Eliane Marti ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Thymic Stromal Lymphopoietin ◽  
Canine Atopic Dermatitis

Preliminary evaluation of cytosine-phosphate-guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis

2017 ◽  
Vol 181 (5) ◽  
pp. 118-118 ◽  
Author(s):  
I. Wagner ◽  
K. J. Geh ◽  
M. Hubert ◽  
G. Winter ◽  
K. Weber ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Mrna Expression ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Interferon Γ ◽  
Preliminary Evaluation ◽  
Cpg Odn ◽  
Canine Atopic Dermatitis ◽  
Group 2 ◽  
Group 1

Cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN) are a promising new immunotherapeutic treatment option for canine atopic dermatitis (AD). The aim of this uncontrolled pilot study was to evaluate clinical and immunological effects of gelatine nanoparticle (GNP)-bound CpG ODN (CpG GNP) on atopic dogs. Eighteen dogs with AD were treated for 8 weeks (group 1, n=8) or 18 weeks (group 2, n=10). Before inclusion and after 2 weeks, 4 weeks, 6 weeks (group 1+2), 8 weeks, 12 weeks and 16 weeks (group 2) 75 µg CpG ODN/dog (bound to 1.5 mg GNP) were injected subcutaneously. Pruritus was evaluated daily by the owner. Lesions were evaluated and serum concentrations and mRNA expressions of interferon-γ, tumour necrosis factor-α, transforming growth factor-β, interleukin (IL) 10 and IL-4 (only mRNA expression) were determined at inclusion and after 8 weeks (group 1+2) and 18 weeks (group 2). Lesions and pruritus improved significantly from baseline to week 8. Mean improvements from baseline to week 18 were 23 per cent and 44 per cent for lesions and pruritus, respectively, an improvement of ≥50 per cent was seen in six out of nine and three out of six dogs, respectively. IL-4 mRNA expression decreased significantly. The results of this study show a clinical improvement of canine AD with CpG GNP comparable to allergen immunotherapy. Controlled studies are needed to confirm these findings.

Sign in / Sign up

Export Citation Format

Share Document